Last reviewed · How we verify
Val, Cel and Met XR High
At a glance
| Generic name | Val, Cel and Met XR High |
|---|---|
| Also known as | Diovan, Celebrex, Glucophage XR, RK-01 |
| Sponsor | ARKAY Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Val, Cel and Met XR High CI brief — competitive landscape report
- Val, Cel and Met XR High updates RSS · CI watch RSS
- ARKAY Therapeutics portfolio CI